P A Davol1, A R Frackelton. 1. Department of Medicine, Roger Williams Medical Center and Brown University, Providence, Rhode Island 02908, USA.
Abstract
BACKGROUND: Basic fibroblast growth factor receptors on DU145 human prostatic carcinoma xenografts serve as targets for the delivery of a growth factor-toxin chimera, basic fibroblast growth factor-saporin (bFGF-SAP), which produces significant antitumor activity in a nude mouse model. However, DU145 tumors often become resistant to prolonged treatment. METHODS: Nude mice bearing DU145 xenografts were intravenously administered bFGF-SAP (0.05 microg/kg weekly for 4 weeks), and a panel of eight tumors was isolated from the treated animals and established in monolayer culture. RESULTS: In cell-survival assays, sensitivity of the treated tumor-derived cell lines to bFGF-SAP (IC50 = 12-100 nM) varied widely from cells derived from a vehicle-treated control tumor (IC50 = 10 nM). A significant inverse correlation was observed between increased IC50 values in vitro and increased tumor growth delay in vivo. Pretreatment of tumor cells with suramin or neutralizing antibodies to bFGF or keratinocyte growth factor (KGF) circumvented resistance in one of the tumor lines, confirming autocrine-mediated resistance. In another tumor subline, a 3-fold decrease in bFGF high-affinity receptor sites, which concurred with a 4-fold decrease in ability to internalize the bFGF ligand, was consistent with a decrease in total cellular expression of the FGF2 receptor (Bek). Resistance was circumvented by alternatively targeting FGF1 receptor (Flg) on these cells with a saporin immunotoxin. CONCLUSIONS: These studies identify alterations in the ligand-targeted receptor as a frequent contributor to resistance arising in DU145 tumors to in vivo treatment with a bFGF receptor-directed-toxin chimera, and provide the basis for designing methods to circumvent resistance for the purpose of enhancing efficacy of receptor-directed therapies in the treatment of prostate cancer. Copyright 1999 Wiley-Liss, Inc.
BACKGROUND: Basic fibroblast growth factor receptors on DU145 humanprostatic carcinoma xenografts serve as targets for the delivery of a growth factor-toxin chimera, basic fibroblast growth factor-saporin (bFGF-SAP), which produces significant antitumor activity in a nude mouse model. However, DU145 tumors often become resistant to prolonged treatment. METHODS:Nude mice bearing DU145 xenografts were intravenously administered bFGF-SAP (0.05 microg/kg weekly for 4 weeks), and a panel of eight tumors was isolated from the treated animals and established in monolayer culture. RESULTS: In cell-survival assays, sensitivity of the treated tumor-derived cell lines to bFGF-SAP (IC50 = 12-100 nM) varied widely from cells derived from a vehicle-treated control tumor (IC50 = 10 nM). A significant inverse correlation was observed between increased IC50 values in vitro and increased tumor growth delay in vivo. Pretreatment of tumor cells with suramin or neutralizing antibodies to bFGF or keratinocyte growth factor (KGF) circumvented resistance in one of the tumor lines, confirming autocrine-mediated resistance. In another tumor subline, a 3-fold decrease in bFGF high-affinity receptor sites, which concurred with a 4-fold decrease in ability to internalize the bFGF ligand, was consistent with a decrease in total cellular expression of the FGF2 receptor (Bek). Resistance was circumvented by alternatively targeting FGF1 receptor (Flg) on these cells with a saporin immunotoxin. CONCLUSIONS: These studies identify alterations in the ligand-targeted receptor as a frequent contributor to resistance arising in DU145 tumors to in vivo treatment with a bFGF receptor-directed-toxin chimera, and provide the basis for designing methods to circumvent resistance for the purpose of enhancing efficacy of receptor-directed therapies in the treatment of prostate cancer. Copyright 1999 Wiley-Liss, Inc.
Authors: Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold Journal: Pharm Res Date: 2014-08-27 Impact factor: 4.200
Authors: Ibrahim A Aljuffali; Jason N Mock; Leah J Costyn; Ha Nguyen; Tamas Nagy; Brian S Cummings; Robert D Arnold Journal: Cancer Biol Ther Date: 2011-09-01 Impact factor: 4.742
Authors: J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Thommey P Thomas; Rameshwer Shukla; Alina Kotlyar; Jola Kukowska-Latallo; James R Baker Journal: Bioorg Med Chem Lett Date: 2009-12-03 Impact factor: 2.823
Authors: Qun Zhao; Luning Wang; Rui Cheng; Leidong Mao; Robert D Arnold; Elizabeth W Howerth; Zhuo G Chen; Simon Platt Journal: Theranostics Date: 2012-01-15 Impact factor: 11.556